The registry will provide researchers with data about adolescent patients suffering from alopecia areata
Research company Thermo Fisher Scientific has launched the international CorEvitas Adolescent Alopecia Areata (AA) Registry.
The registry aims to provide researchers with robust data about AA adolescent patients, including treatment patterns and the safety and effectiveness of new therapies.
“This registry will provide researchers with real-world, concrete evidence about the health status and treatment patterns of these patients,” said Thermo Fisher’s global head of scientific affairs, CorEvitas, Dr Peter Wahl.
“The research community will be able to contextualize both the effectiveness and safety of newly approved treatments for adolescents with AA.”
AA is a chronic autoimmune condition affecting about 160 million people worldwide. While it affects people of all ages, it is more prevalent among children and adolescents, affecting their hair, skin, nails and psychosocial functioning.
The data will support AA research, informing on the impact of the autoimmune disease on physical and psychosocial health.
The registry will study patient history, disease progression, medication use patterns and their effectiveness, and the incidence of safety events related to treatments.
A team of dermatologists, from Yale School of Medicine, Harvard Medical School and Connecticut Dermatology Physicians, will provide scientific guidance.
The registry is active in Europe and the USA and complements another CorEvitas registry for adults with AA, which was launched in 2023.
Thermo Fisher Scientific’s CorEvitas programme operates 12 independent registries focused on autoimmune and inflammatory diseases.
